Breast, prostatic and pancreatic cancers alter the zinc (Zn) metabolism. Mixed analyses of urinary Zn concentrations ([Zn]) and Zn secure isotope compositions (δ66Zn) might present a non-invasive method for tracing malignancy-induced Zn dyshomeostasis. On this research, we measured [Zn] and δ66Zn in urine from prostate (n = 22), breast (n = 16) and from ladies with benign breast illness (n = 14) and in contrast these to age-matched wholesome controls and revealed knowledge for pancreatic most cancers (n = 17). Our outcomes present most cancers-induced modifications are mirrored in greater urinary [Zn] and decrease urinary δ66Zn for pancreatic and prostate most cancers and benign breast illness when in comparison with wholesome controls.
For prostate most cancers, low [Zn] and excessive δ66Zn for sufferers of low-risk illness progresses in direction of excessive [Zn] and low δ66Zn for the higher-risk sufferers, demonstrates that [Zn] and δ66Zn in urine might function a dependable prognostic device. Urinary excretion of isotopically mild Zn by sufferers with prostatic and pancreatic most cancers might be the results of elevated reactive oxygen species in most cancersous cells, which limits the scavenging of hydroxyl radicals and thus facilitates the oxidation of metalloproteins with sulfur-rich ligands.
Urine from malignant breast most cancers sufferers reveals undistinguishable δ66Zn to wholesome controls, implying that the expression of metalloproteins with sulfur-rich ligands is stronger in breast most cancers tissues. In conclusion, urinary δ66Zn might present a non-invasive diagnostic device for pancreatic most cancers and help illness prognosis for prostate most cancers. These findings ought to translate to complete transverse and longitudinal cohort research in future.
Pancreatic strong pseudopapillary neoplasms (SPNs) are uncommon borderline tumours primarily affecting younger feminine sufferers. The variety of sufferers recognized with SPNs has elevated considerably within the final a long time owing to the elevated use of cross-sectional imaging investigating totally different stomach signs, while a major proportion are by the way found through the means of evaluating different pathologies. We herein current our institutional expertise of sufferers with SPN who underwent healing resection specializing in scientific, pathological options, and the long-term outcomes.
Throughout the inclusion interval, a complete of 19 sufferers had a pathological analysis of SPNs after surgical resection. Sixteen of them have been feminine (84%), whereas the median affected person age was 30 (vary 16-66) years. 9 sufferers (47%) underwent distal pancreatectomy and splenectomy, 2 (11%) underwent spleen preserving distal pancreatectomy, 6 (32%) underwent pancreatoduodenectomy, one (5%) underwent whole pancreatectomy, and one (5%) central pancreatectomy. Seventeen sufferers underwent R0 resection. Throughout a median follow-up of 23 months, no tumour recurrence or dying was recorded.
Supramolecular Nanofibrils Fashioned by Coassembly of Clinically Accepted Medicine for Tumor Photothermal Immunotherapy
Pancreatic most cancers, one of the deadly malignancies, compromises the efficiency of conventional therapeutic regimens within the clinic due to stromal resistance to systemic drug supply and poor prognosis brought on by tumor metastasis. Due to this fact, a biocompatible therapeutic paradigm that may successfully inhibit pancreatic tumor development whereas concurrently eliminating tumor metastasis is urgently wanted. Herein, supramolecular nanofibrils are fabricated by means of coassembly of clinically authorised immunomodulatory thymopentin and near-infrared indocyanine inexperienced for localized photothermal immunotherapy of pancreatic tumors.
The ensuing long-range ordered fibrous nanodrugs present improved photophysical capabilities for fluorescence imaging and photothermal conversion and considerably promote the proliferation and differentiation of antitumor immune cells. Therefore, the combination of fast photothermal remedy and reasonable immunomodulation for inhibiting tumor development and eliminating tumor metastasis is promising. The utilization of clinically authorised molecules to assemble nanodrugs administered by way of localized injection amplifies the complementary photothermal immunotherapeutic results of the elements, creating alternatives for scientific translation as a therapy for pancreatic most cancers.
The somatic mutation knowledge, transcriptome profiles and scientific data have been downloaded from the Most cancers Genome Atlas database. Gene expression distinction, Gene ontology, KEGG, gene set enrichment analyses and “CIBERSORT” algorithm have been carried out to display screen differentially expressed genes, enriched capabilities or pathways and immune infiltrates variations between excessive and low TMB teams. Single pattern gene set enrichment and unsupervised consensus clustering analyses have been used for immunity grouping. Immune cell infiltration and expressions of HLA and checkpoint genes have been investigated.
Stearoyl-CoA Desaturase 1 Potentiates Hypoxic plus Nutrient-Disadvantaged Pancreatic Most cancers Cell Ferroptosis Resistance
Hypoxia and nutrient hunger (H/NS) microenvironment, a notable attribute of pancreatic carcinoma, performs a important function in cell dying resistance and tumor recurrence. Nevertheless, its function in ferroptosis stays to be categorised. Right here, we discovered that H/NS contributed to the pancreatic most cancers cell ferroptosis resistance relying on the altered intracellular lipid compositions. Mechanistically, H/NS induced the upregulation of stearoyl-CoA desaturase 1 (SCD1), which promoted monounsaturated fatty acids (MUFAs) synthesis and guarded in opposition to lipid peroxidation.
Surprisingly, SCD1 confirmed a powerful correlation with antiferroptosis gene expression. Furthermore, short-hairpin RNA-based knockdown of SCD1 enhanced erastin-induced ferroptosis in vitro underneath H/NS. Lastly, our outcomes display the synergistic impact of erastin and A939572, a particular SCD1 inhibitor, in dictating pancreatic carcinoma subcutaneous ferroptotic dying. Taken collectively, our findings reveal a brand new function of the H/NS microenvironment in opposition to ferroptosis and recommend a possible therapeutic technique for overcoming ferroptosis resistance in pancreatic most cancers cells.
 CancerSeq™ Plus Paraffin Tissue Tumor Sections: Breast |
|
T2235086-SC |
Biochain |
5 curls |
EUR 779 |
 CancerSeq™ Paraffin Tissue Tumor Slides: Skin Melanoma |
|
T2235218A-ST |
Biochain |
5 Slides |
EUR 572 |
 CancerSeq™ Plus Paraffin Tissue Tumor Sections: Stomach |
|
T2235248-SC |
Biochain |
5 curls |
EUR 779 |
 CancerSeq™ Plus Paraffin Tissue Tumor Sections: Thyroid |
|
T2235265-SC |
Biochain |
5 curls |
EUR 779 |
) Cancers of 15 major types, 39 cases (2mm) |
|
MTU391 |
Pantomics |
1 |
EUR 228 |
|
Description: 15 major types of cancer covering top 10 cancers both in the East and West from 12 anatomic sites. Most of the tumor types have duplicates from different patients with corresponding uninvolved tissues as controls with grading and TNM staging data.. |
) Cancers of 15 major types, 48 cases (1.5mm) |
|
MTU481 |
Pantomics |
1 |
EUR 193.2 |
|
Description: Multi tumor tissue array, 48 cases of 15 cancer types. Most types have duplicates or triplicates from different patients with grading and TNM staging data. |
) Cancers/tumors of 40 types, 102 cases (1.5mm) |
|
MTU1021 |
Pantomics |
1 |
EUR 300 |
|
Description: 40 types of tumors, non-overlapping with MTU951, covering all the common benign, malignant and metastatic entities originated from 27 anatomic sites. Most of them have duplicates or triplicates from different individuals with corresponding uninvolved tissues as controls along with grading and TNM staging data. |
) Cancers/tumors of 40 types, 95 cases (1.5mm) |
|
MTU951 |
Pantomics |
1 |
EUR 300 |
|
Description: 40 types of tumors covering all the common benign, malignant and metastatic entities originated from 27 anatomic sites. Most of them have duplicates or triplicates from different individuals with corresponding uninvolved tissues as controls with grading and TNM staging data. |
 Antibody) Mutated In Colorectal Cancers (MCC) Antibody |
|
abx235046-100ug |
Abbexa |
100 ug |
EUR 661.2 |
|
|
Mutated In Colorectal Cancers (MCC) Antibody |
|
20-abx210997 |
Abbexa |
|
|
|
|
Mutated In Colorectal Cancers (MCC) Antibody |
|
20-abx210998 |
Abbexa |
|
|
|
|
Mutated In Colorectal Cancers (MCC) Antibody |
|
20-abx113896 |
Abbexa |
|
|
|
|
Mutated In Colorectal Cancers (MCC) Antibody |
|
abx029386-400ul |
Abbexa |
400 ul |
EUR 627.6 |
|
|
Mutated In Colorectal Cancers (MCC) Antibody |
|
abx029386-80l |
Abbexa |
80 µl |
EUR 343.2 |
|
|
Mutated In Colorectal Cancers (MCC) Antibody |
|
20-abx123165 |
Abbexa |
-
EUR 493.20
-
EUR 710.40
-
EUR 376.80
|
|
|
|
 MCC Antibody / Mutated in Colorectal Cancers |
|
RQ6655 |
NSJ Bioreagents |
100ug |
EUR 356.15 |
|
Description: MUTATED IN COLORECTAL CANCERS (MCC) is a tumor suppressor gene. It is mapped to 5q22.2. This gene suppresses cell proliferation and the Wnt/b-catenin pathway in colorectal cancer cells. MCC also Inhibits DNA binding of b-catenin/TCF/LEF transcription factors, and it is Involved in cell migration independently of RAC1, CDC42 and p21-activated kinase (PAK) activation. What's more, MCC can interact with SCRIB (via phosphorylated PDZ-binding motif), EZR, SNX27, SLC9A3R1 and SLC9A3R2. |
 Mouse mAb) SNCG (breast cancer-specific protein 1) Mouse mAb |
|
E2220104 |
EnoGene |
100ul |
EUR 225 |
|
Description: Available in various conjugation types. |
 Antibody) SNCG (breast cancer-specific protein 1) Antibody |
|
BF0110 |
Affbiotech |
200ul |
EUR 540 |
) SNCG Antibody (breast cancer-specific protein 1) |
|
E10-20084 |
EnoGene |
100μg/100μl |
EUR 225 |
|
Description: Available in various conjugation types. |
 Human colon cancer-specific antigen-4,CCSA-4 ELISA kit |
|
201-12-1665 |
SunredBio |
96 tests |
EUR 528 |
|
|
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
 Human colon cancer-specific antigen-2,CCSA-2 ELISA kit |
|
201-12-1681 |
SunredBio |
96 tests |
EUR 528 |
|
|
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
 Human colon cancer-specific antigen-3,CCSA-3 ELISA kit |
|
201-12-1721 |
SunredBio |
96 tests |
EUR 528 |
|
|
|
Description: A quantitative ELISA kit for measuring Human in samples from biological fluids. |
 Antibody) Breast Cancer-Specific Gene 1 Protein (SNCG) Antibody |
|
abx011543-100ul |
Abbexa |
100 ul |
EUR 493.2 |
|
|
 Human colon cancer-specific antigen-2, CCSA-2 ELISA kit |
|
CSB-E11291h-24T |
Cusabio |
1 plate of 24 wells |
EUR 198 |
|
|
|
Description: Quantitativesandwich ELISA kit for measuring Human colon cancer-specific antigen-2, CCSA-2 in samples from serum, plasma, cell culture supernates, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price. |
Human colon cancer-specific antigen-2, CCSA-2 ELISA kit |
|
1-CSB-E11291h |
Cusabio |
-
EUR 964.80
-
EUR 6118.80
-
EUR 3244.80
|
- 1 plate of 96 wells
- 10 plates of 96 wells each
- 5 plates of 96 wells each
|
|
|
|
Description: Quantitativesandwich ELISA kit for measuring Human colon cancer-specific antigen-2, CCSA-2 in samples from serum, plasma, cell culture supernates, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits. |
 (1H10D2)) anti-SNCG (breast cancer-specific protein 1) (1H10D2) |
|
LF-MA30069 |
Abfrontier |
100 ul |
EUR 534 |
|
Description: Mouse Monoclonal to SNCG (breast cancer-specific protein 1) |
ELISA Kit) Human colon cancer-specific antigen-4(CCSA-4)ELISA Kit |
|
GA-E1681HM-48T |
GenAsia Biotech |
48T |
EUR 346.8 |
Human colon cancer-specific antigen-4(CCSA-4)ELISA Kit |
|
GA-E1681HM-96T |
GenAsia Biotech |
96T |
EUR 559.2 |
ELISA Kit) Human colon cancer-specific antigen-2(CCSA-2)ELISA Kit |
|
GA-E1697HM-48T |
GenAsia Biotech |
48T |
EUR 346.8 |
Human colon cancer-specific antigen-2(CCSA-2)ELISA Kit |
|
GA-E1697HM-96T |
GenAsia Biotech |
96T |
EUR 559.2 |
ELISA Kit) Human colon cancer-specific antigen-3(CCSA-3)ELISA Kit |
|
GA-E1737HM-48T |
GenAsia Biotech |
48T |
EUR 346.8 |
Human colon cancer-specific antigen-3(CCSA-3)ELISA Kit |
|
GA-E1737HM-96T |
GenAsia Biotech |
96T |
EUR 559.2 |
Human colon cancer-specific antigen-4(CCSA-4)ELISA Kit |
|
QY-E03945 |
Qayee Biotechnology |
96T |
EUR 433.2 |
Human colon cancer-specific antigen-3(CCSA-3)ELISA Kit |
|
QY-E03946 |
Qayee Biotechnology |
96T |
EUR 433.2 |
Human colon cancer-specific antigen-2(CCSA-2)ELISA Kit |
|
QY-E03947 |
Qayee Biotechnology |
96T |
EUR 433.2 |
 ELISA Kit) Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
KTE62591-96T5 |
Abbkine |
96 T×5 |
EUR 2629 |
|
Description: This Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit employs a two-site sandwich ELISA to quantitate CCSA-2. |
Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit |
|
KTE62591-96T50 |
Abbkine |
96 T×50 |
EUR 24569 |
|
Description: This Human Colon cancer-specific antigen-2 (CCSA-2) ELISA Kit employs a two-site sandwich ELISA to quantitate CCSA-2. |
Human colon cancer-specific antigen-2,CCSA-2 ELISA kit |
|
EKC33236-48T |
Biomatik Corporation |
48T |
EUR 535.99 |
Human colon cancer-specific antigen-2,CCSA-2 ELISA kit |
|
EKC33236-5x96T |
Biomatik Corporation |
5x96T |
EUR 3637.08 |
Human colon cancer-specific antigen-2,CCSA-2 ELISA kit |
|
EKC33236-96T |
Biomatik Corporation |
96T |
EUR 765.7 |
Human colon cancer-specific antigen-3,CCSA-3 ELISA kit |
|
YLA0511HU-48T |
Shanghai YL Biotech |
48T |
EUR 435 |
Human colon cancer-specific antigen-3,CCSA-3 ELISA kit |
|
YLA0511HU-96T |
Shanghai YL Biotech |
96T |
EUR 562.5 |
Human colon cancer-specific antigen-2,CCSA-2 ELISA kit |
|
YLA0166HU-48T |
Shanghai YL Biotech |
48T |
EUR 435 |
Human colon cancer-specific antigen-2,CCSA-2 ELISA kit |
|
YLA0166HU-96T |
Shanghai YL Biotech |
96T |
EUR 562.5 |
Human colon cancer-specific antigen-4,CCSA-4 ELISA kit |
|
YLA0017HU-48T |
Shanghai YL Biotech |
48T |
EUR 435 |
Human colon cancer-specific antigen-4,CCSA-4 ELISA kit |
|
YLA0017HU-96T |
Shanghai YL Biotech |
96T |
EUR 562.5 |
 Human colon cancer-specific antigen-2,CCSA-2 ELISA Kit |
|
SL0493Hu |
Sunlong |
96 Tests |
EUR 468 |
|
|
 Human colon cancer-specific antigen-3,CCSA-3 ELISA Kit |
|
SL0494Hu |
Sunlong |
96 Tests |
EUR 468 |
|
|
 Human colon cancer-specific antigen-4,CCSA-4 ELISA Kit |
|
SL0495Hu |
Sunlong |
96 Tests |
EUR 468 |
|
|
) ELISA kit for Human Colon cancer-specific antigen-2 (CCSA-2) |
|
KTE62591-48T |
Abbkine |
48T |
EUR 398.4 |
|
|
|
Description: Quantitative sandwich ELISA for measuring Human Colon cancer-specific antigen-2 (CCSA-2) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Human Colon cancer-specific antigen-2 (CCSA-2) |
|
KTE62591-5platesof96wells |
Abbkine |
5 plates of 96 wells |
EUR 2538 |
|
|
|
Description: Quantitative sandwich ELISA for measuring Human Colon cancer-specific antigen-2 (CCSA-2) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Human Colon cancer-specific antigen-2 (CCSA-2) |
|
KTE62591-96T |
Abbkine |
96T |
EUR 646.8 |
|
|
|
Description: Quantitative sandwich ELISA for measuring Human Colon cancer-specific antigen-2 (CCSA-2) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
) ELISA kit for Human Colon cancer-specific antigen-4 (CCSA-4) |
|
KTE62592-48T |
Abbkine |
48T |
EUR 398.4 |
|
|
|
Description: Quantitative sandwich ELISA for measuring Human Colon cancer-specific antigen-4 (CCSA-4) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Human Colon cancer-specific antigen-4 (CCSA-4) |
|
KTE62592-5platesof96wells |
Abbkine |
5 plates of 96 wells |
EUR 2538 |
|
|
|
Description: Quantitative sandwich ELISA for measuring Human Colon cancer-specific antigen-4 (CCSA-4) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
ELISA kit for Human Colon cancer-specific antigen-4 (CCSA-4) |
|
KTE62592-96T |
Abbkine |
96T |
EUR 646.8 |
|
|
|
Description: Quantitative sandwich ELISA for measuring Human Colon cancer-specific antigen-4 (CCSA-4) in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids. |
 Blocking Peptide) SNCG (breast cancer-specific protein 1) Blocking Peptide |
|
BF0110-BP |
Affbiotech |
1mg |
EUR 234 |
 Antibody, Clone: 1H10D2) Monoclonal SNCG (breast cancer-specific protein 1) Antibody, Clone: 1H10D2 |
|
APR10168G |
Leading Biology |
0.1ml |
EUR 580.8 |
|
Description: A Monoclonal antibody against Human SNCG (breast cancer-specific protein 1). The antibodies are raised in Mouse and are from clone 1H10D2. This antibody is applicable in WB and IHC, E |
 Metastatic Tumor Tissue Array - 18 cases of metastatic cancers from 4 anatomic sites |
|
Z7020073 |
Biochain |
5 slides |
EUR 1125.6 |
|
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
 Metastatic Tumor Tissue Array - 48 cases of metastatic cancers from 8 anatomic sites |
|
Z7020074 |
Biochain |
5 slides |
EUR 1657.2 |
|
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
 Stomach Tumor Tissue Array - 36 cases of gastric cancers of various grades and stages, and 12 cases of normal and inflam |
|
Z7020049 |
Biochain |
5 slides |
EUR 1657.2 |
|
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
 Esophageal Tumor Tissue Array - 70 cases of esophageal cancers of different grades and stages, and 5 cases of normal and |
|
Z7020026 |
Biochain |
5 slides |
EUR 1657.2 |
|
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
 and uninvolved b) Bladder Tumor Tissue Array - 66 cores including bladder cancers of various grades and stages (29 cases) and uninvolved b |
|
Z7020106 |
Biochain |
5 slides |
EUR 1657.2 |
|
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
 Pancreas Tumor Tissue Array - 20 cases of pancreatic cancers and 4 cases of normal and non-malignant pancreatic tissues. |
|
Z7020090 |
Biochain |
5 slides |
EUR 1657.2 |
|
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
 Colon cancer and lung cancer tissue array |
|
CLC601 |
TissueArray |
each |
EUR 306 |
|
Description: Colon cancer and lung cancer tissue array, including TNM and pathology grade, 60 cases/60 cores |
 Stomach cancer and lung cancer tissue array |
|
SLC601 |
TissueArray |
each |
EUR 306 |
|
Description: Stomach cancer and lung cancer tissue array, including TNM and pathology grade, 60 cases/60 cores |
 Human Cancer PrimaCell15: Skin Cancer Cells |
|
2-96038 |
CHI Scientific |
1 Kit |
Ask for price |
 Colon cancer with cancer adjacent tissue array |
|
T051b |
TissueArray |
each |
EUR 48 |
|
Description: Colon cancer with cancer adjacent tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T051a |
 Kidney cancer tissue array with matched cancer adjacent and cancer kidney adjacent tissue |
|
KD991b |
TissueArray |
each |
EUR 270 |
|
Description: Kidney cancer tissue array with matched cancer adjacent and cancer kidney adjacent tissue, 33 cases/ 99 cores, replacing KD991a |
 Protein) Human Cancer Antigen CA125 (Ovarian Cancer) Protein |
|
abx061590-100kU |
Abbexa |
100 kU |
EUR 1446 |
|
|
 Breast cancer with cancer adjacent breast tissue array |
|
BC081116e |
TissueArray |
each |
EUR 306 |
|
Description: Breast cancer with cancer adjacent breast tissue array, including invasive carcinoma of no special type, breast carcinoma with apocrine differentiation and AT tissue,pat hology grade, IHC (ER/PR/Her-2/Ki67) info, TNM/Stage (AJCC 7th edition), 107 cases/110 cores (core size 1.5mm), replacing BC081116d |
 Cervix cancer tissue array with cancer adjacent tissue |
|
CR501a |
TissueArray |
each |
EUR 234 |
|
Description: Cervix cancer tissue array with cancer adjacent tissue, including TNM, clinical stage and pathology grade, 50 cases/50 cores, replacing CR501 |
 Lung cancer with matched cancer adjacent lung tissue array |
|
LC481 |
TissueArray |
each |
EUR 168 |
|
Description: Lung cancer with matched cancer adjacent lung tissue array, including pathology grade, TNM and clinical stage, 12 cases/48 cores |
 Human Cancer PrimaCell15: Skin Cancer Cells Growth Medium |
|
9-46038 |
CHI Scientific |
5 x 100 ml |
Ask for price |
 Human Cancer Tissue Preparation Buffer 15: Skin Cancer Cells |
|
9-80038 |
CHI Scientific |
1 x 100 ml |
Ask for price |
 Stomach cancer with matched cancer adjacent tissue array |
|
ST1504 |
TissueArray |
each |
EUR 258 |
|
Description: Stomach cancer with matched cancer adjacent tissue array, including pathology grade, TNM and clinical stage, 50 cases/150 cores |
 Lung cancer |
|
LC751 |
TissueArray |
each |
EUR 234 |
|
Description: Lung cancer, matched cancer adjacent and normal adjacent lung tissue array, including pathology grade, TNM and clinical stage (AJCC 8.0), 25 cases/75 cores (core size 1.5mm),Recent Year Collection |
 Liver cancer with matched cancer adjacent liver tissue array |
|
LV1505a |
TissueArray |
each |
EUR 258 |
|
Description: Liver cancer with matched cancer adjacent liver tissue array, including pathology grade, TNM and clinical stage, replacing LV1505 |
 Prostate cancer tissue array with cancer adjacent tissues |
|
PR721 |
TissueArray |
each |
EUR 306 |
|
Description: Prostate cancer tissue array with cancer adjacent tissues, including WHO grade, gleason grade, gleason score, TNM and stage info, 24 cases/72 cores |
 Colon cancer tissue array with matched cancer adjacent tissue |
|
BC05023a |
TissueArray |
each |
EUR 270 |
|
Description: Colon cancer tissue array with matched cancer adjacent tissue, including TNM and pathology grade, 18 cases/ 54 cores, replacing BC05023 |
Colon cancer tissue array with matched cancer adjacent tissue |
|
CO801b |
TissueArray |
each |
EUR 270 |
|
Description: Colon cancer tissue array with matched cancer adjacent tissue, including pathology grade, TNM and clinical stage, 40 cases/80 cores, replcing CO801a |
 Pancreatic cancer tissue array with cancer adjacent tissue |
|
PA242e |
TissueArray |
each |
EUR 66 |
|
Description: Pancreatic cancer tissue array with cancer adjacent tissue, including pathology grade, TNM and clinical stage, 12 cases/24 cores, replacing PA242d |
 Liver cancer |
|
BC03117 |
TissueArray |
each |
EUR 306 |
|
Description: Liver cancer, liver cirrhosis tissue array with normal tissue as control, including TNM, clinical stage, pathology grade and history of hepatitis, 70 cases/ 80 cores, replaced by BC03117a |
 Breast cancer with matched cancer adjacent breast tissue array |
|
BR804b |
TissueArray |
each |
EUR 306 |
|
Description: Breast cancer with matched cancer adjacent breast tissue array, including pathology grade, TNM, clinical stage and IHC markers (ER, PR, Her-2 and Ki67), 40 cases/80 cores, replacing BR804a |
 Lung cancer with matched adjacent and cancer adjacent tissue array |
|
BC04022a |
TissueArray |
each |
EUR 168 |
|
Description: Lung cancer with matched adjacent and cancer adjacent tissue array, including TNM, clinical stage and pathology grade, 3 cores/case, replacing BC04022 |
 Breast cancer |
|
BR1008b |
TissueArray |
each |
EUR 306 |
|
Description: Breast cancer, lymph node metastatic carcinoma and adjacent normal tissue array, including pathology grade, TNM, clinical stage, and ER/PR/Her2 result, 100 cases/100 cores, replacing BR1008a |
Breast cancer |
|
BR724 |
TissueArray |
each |
EUR 270 |
|
Description: Breast cancer, adjacent and adjacent normal tissue array, 66 cases/72 cores |
Breast cancer |
|
BR725 |
TissueArray |
each |
EUR 270 |
|
Description: Breast cancer, adjacent and adjacent normal tissue array, 68 cases/72 cores |
 Kidney cancer with matched cancer adjacent normal tissue test array |
|
KD241 |
TissueArray |
each |
EUR 48 |
|
Description: Kidney cancer with matched cancer adjacent normal tissue test array, including TNM and clinical stage, 6 cases/24 cores |
Kidney cancer with matched cancer adjacent normal tissue test array |
|
KD241a |
TissueArray |
each |
EUR 66 |
|
Description: Kidney cancer with matched cancer adjacent normal tissue test array, including TNM and clinical stage, 6 cases/24 cores, replacing KD241 |
) Liver primary cancer and metastatic cancer tissue array (most are stage IV) |
|
LV1221 |
TissueArray |
each |
EUR 336 |
|
Description: Liver primary cancer and metastatic cancer tissue array (most are stage IV), containing NAT sample, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, carcinoid, adenosquamous carcinoma, mixed carcinoma, metastatic carcinoma samples, 100 cases/122 cores |
 Colon primary cancer with metastastic cancer and normal tissue array |
|
CO702d |
TissueArray |
each |
EUR 270 |
|
Description: Colon primary cancer with metastastic cancer and normal tissue array, including pathology grade, TNM and clinical stage, 65 cases/69 cores, repalcing CO702c |
 Gall bladder cancer with matched cancer adjacent normal tissue array |
|
GA461a |
TissueArray |
each |
EUR 168 |
|
Description: Gall bladder cancer with matched cancer adjacent normal tissue array, including pathology grade, TNM and clinical stage, 20 cases/46 cores (core size 1.5mm),replacing GA461 |
 Breast cancer TMA |
|
BR602 |
TissueArray |
each |
EUR 270 |
|
Description: Breast cancer TMA, 3 samples have matched cancer adjacent tissue samples, including pathology grade, TNM and clinical stage (reference AJCC 8th version), 57 cases/60 cores (Core Size 1.5mm), recent tear collections |
 Stomach cancer |
|
ST1451a |
TissueArray |
each |
EUR 540 |
|
Description: Stomach cancer, matched NAT, matched metastasis tissue (recent year collection samples), including pathology grade, TNM and clinical stage, 71 cases/145 cores, replacing ST1451 |
 Breast cancer tissue array with cancer adjacent breast tissue as control |
|
BR208a |
TissueArray |
each |
EUR 474 |
|
Description: Breast cancer tissue array with cancer adjacent breast tissue as control, including TNM, clinical stage and pathology grade, 69 cases/ 207 cores. |
 Kidney cancer tissue array with matched cancer adjacent tissue as control |
|
KD1503 |
TissueArray |
each |
EUR 306 |
|
Description: Kidney cancer tissue array with matched cancer adjacent tissue as control, including TNM, stage and pathology grade, 50 cases/ 150 cores |
 Kidney cancer tissue array with matched cancer adjacent kidney tissue |
|
KD2601a |
TissueArray |
each |
EUR 354 |
|
Description: Kidney cancer tissue array with matched cancer adjacent kidney tissue,including TNM, clinical stage and pathology grade, 65 cases/ 260 cores, replacing KD2061 |
 Rectum cancer tissue array with matched cancer adjacent tissue as control |
|
RE1504 |
TissueArray |
each |
EUR 258 |
|
Description: Rectum cancer tissue array with matched cancer adjacent tissue as control, including TNM, clinical stage and pathology grade, 50 cases/ 150 cores |
 Prostate cancer |
|
PR632 |
TissueArray |
each |
EUR 306 |
|
Description: Prostate cancer, hyperplasia with normal tissue array, including pathology grade, Gleason grade, Gleason score, TNM and clinical stage, 21cases/63 cores |
 Esophagus cancer with matched cancer adjacent esophagus tissue array |
|
ES1025 |
TissueArray |
each |
EUR 354 |
|
Description: Esophagus cancer with matched cancer adjacent esophagus tissue array, including pathology grade, TNM and clinical stage (AJCC 8.0), 51 cases/102 cores (1.5 mm). |
 Stomach cancer tissue array with matched cancer adjacent tissue as control |
|
ST1505 |
TissueArray |
each |
EUR 258 |
|
Description: Stomach cancer tissue array with matched cancer adjacent tissue as control, including TNM, stage and pathology grade, 50 cases/150 cores |
 Esophagus cancer |
|
ES1041 |
TissueArray |
each |
EUR 306 |
|
Description: Esophagus cancer, cancer adjacent and normal esophagus tissue array, including squamous cell carcinoma,adenocarcinoma,undifferentiated carcinoma, AT and normal tissue, pathology grade, TNM and clinical stage (AJCC 8.0), 104 cases/104 cores (core size 1.5mm), replacing ES1021 |
 Kidney cancer (CCRCC |
|
KD1201 |
TissueArray |
each |
EUR 306 |
|
Description: Kidney cancer (CCRCC,PRCC,CRCC)with kidney tissue array,including ISUP Grade, TNM/Stage, 120 cases/120 cores (core size 1.0mm ), (Previous Item# is BC07115b) |
) Cancer of the lung, 102 cases (1.5mm) |
|
LUC1021 |
Pantomics |
1 |
EUR 300 |
|
Description: Lung cancer tissue array, 102 cases of normal/benign (5 cases) and cancer (97 cases with grading and TNM staging data.) tissues |
) Cancer of the lung, 228 cases (1.1mm) |
|
LUC2281 |
Pantomics |
1 |
EUR 552 |
|
Description: Lung cancer tissue array containing 8 cases of normal/benign conditions and 220 cases of cancers with grading and TNM staging data. |
 Lung Cancer Exosome |
|
P141-LG |
101Bio |
- |
Ask for price |
 Top 4 types of cancer (colon |
|
TP241a |
TissueArray |
each |
EUR 48 |
|
Description: Top 4 types of cancer (colon, breast, lung and prostate) tissue array, including TNM, clinical stage and pathology grade, 12 cases/24 cores, replacing TP241 |
Top 4 types of cancer (colon |
|
TP241b |
TissueArray |
each |
EUR 48 |
|
Description: Top 4 types of cancer (colon, breast, lung and prostate) tissue array, including TNM, clinical stage and pathology grade, 12 cases/24 cores, replacing TP241a |
Top 4 types of cancer (colon |
|
TP242f |
TissueArray |
each |
EUR 90 |
|
Description: Top 4 types of cancer (colon, breast, lung and prosate) with normal tissue array, including colon adenocarcinoma, breast invasive carcinoma of no special type, prostate adenocarcinoma, lung squamous cell carcinoma, lung adenocarcinoma, grade, TNM and clinical state (AJCC 8.0), 24 cases/24 cores (core size 1.5mm), replacing TP242e, Recent Year Collection |
 Pancreatic cancer tissue array with matched cancer adjacent tissue as control |
|
PA811 |
TissueArray |
each |
EUR 306 |
|
Description: Pancreatic cancer tissue array with matched cancer adjacent tissue as control, including TNM, stage and pathology grade, 27 cases/ 81 cores |
 Colorectal cancer |
|
CRM1501 |
TissueArray |
each |
EUR 420 |
|
Description: Colorectal cancer, 150 cases. |
) Cancer of the colon, 102 cases (1.5mm) |
|
COC1021 |
Pantomics |
1 |
EUR 300 |
|
Description: Colon cancer tissue array, 102 cases of normal/benign (5 cases) and cancer (97 cases) tissues with grading and TNM staging data. |
) Cancer of the colon, 228 cases (1.1mm) |
|
COC2281 |
Pantomics |
1 |
EUR 552 |
|
Description: Colon cancer tissue array containing 8 cases of normal/benign conditions and 220 cases of cancers with grading and TNM staging data. |
) Cancer of the liver, 102 cases (1.5mm) |
|
LVC1021 |
Pantomics |
1 |
EUR 300 |
|
Description: Liver cancer tissue array, 102 cases of normal/benign (5 cases) and cancer (97 cases) tissues with grading and TNM staging data |
) Cancer of the liver, 228 cases (1.1mm) |
|
LVC2281 |
Pantomics |
1 |
EUR 552 |
|
Description: Liver cancer tissue array containing 8 cases of normal/benign conditions and 220 cases of cancers with grading and TNM staging data. |
, set 1) Cancer of the lung, 75 cases (1.1mm), set 1 |
|
LUC1501 |
Pantomics |
1 |
EUR 300 |
|
Description: Lung cancer tissue array, set 1, non-overlapping with LUC1502 or LUC1503, 150 cores from normal/benign (5 cases) and cancer (70 cases with grading and TNM staging data) tissues in duplicates. |
, set 2) Cancer of the lung, 75 cases (1.1mm), set 2 |
|
LUC1502 |
Pantomics |
1 |
EUR 300 |
|
Description: Lung cancer tissue array, set 2, non-overlapping with LUC1501 or LUC1502, 150 cores from normal/benign (5 cases) and cancer (70 cases with grading and TNM staging data) tissues in duplicates. |
, set 3) Cancer of the lung, 75 cases (1.1mm), set 3 |
|
LUC1503 |
Pantomics |
1 |
EUR 300 |
|
Description: Lung cancer tissue array, set 3, non-overlapping with LUC1501 or LUC1502, 150 cores from normal/benign (5 cases) and cancer (70 cases with grading and TNM staging data) tissues in duplicates. |
 Liver Cancer Exosome |
|
P141-LV |
101Bio |
- |
Ask for price |
 Lung Cancer Exosome RNA |
|
P241-LG |
101Bio |
- |
Ask for price |
) Cancer of the ovary, 102 cases (1.5mm) |
|
OVC1021 |
Pantomics |
1 |
EUR 300 |
|
Description: Ovary cancer tissue array, 102 cases of normal/benign (5 cases) and cancer (97 cases) tissues with grading and TNM staging data. |
) Cancer of the ovary, 228 cases (1.1mm) |
|
OVC2281 |
Pantomics |
1 |
EUR 552 |
|
Description: Ovary cancer tissue array containing 8 cases of normal/benign conditions and 220 cases of cancers with grading and TNM staging data. |
A complete of 608 differentially expressed genes have been recognized between excessive and low TMB teams, KEGG base excision restore and DNA replication pathways have been enriched in excessive TMB group. Infiltration ranges of M0 macrophages have been greater and dendritic resting cells have been decrease in excessive TMB group. Lastly, a nomogram mannequin integrating TMB and immune infiltration was established.
